News Related to Midomafetamine

Related coverage linked through entity extraction aliases.

Compass Pathways Reports Positive Phase 3 Results for COMP360 in Treatment-Resistant Depression

Mar 09, 2026

Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.

Compass Pathways Reports Positive Phase 3 Data for Psilocybin Depression Treatment

Feb 16, 2026

Compass Pathways' COMP360 synthetic psilocybin met primary endpoints in Phase 3 trials for treatment-resistant depression, with the company planning to submit a new drug application in Q4 2026.